Becton, Dickinson and Company (BD) reported a revenue increase of 8.2% for the fiscal year ending September 30, 2025, totaling $21.840 billion, compared to $20.178 billion in the previous year. The growth was driven by a 4.8% contribution from the acquisition of Edwards Lifesciences’ Critical Care product group, now known as BD Advanced Patient Monitoring, which was completed in September 2024. The company also noted a 3.2% increase in volume, although this was partially offset by a 0.3% decline in pricing and a minimal foreign currency impact.
In terms of profitability, BD's net income from continuing operations was $1.678 billion, or $5.82 per diluted share, slightly down from $1.705 billion, or $5.86 per diluted share, in the prior year. The decrease in net income was attributed to higher integration, restructuring, and transaction expenses, which totaled $408 million in 2025, compared to $458 million in 2024. Additionally, the company faced increased interest expenses due to higher debt levels, which rose to $613 million from $528 million in the previous year.
Strategically, BD underwent significant organizational changes, restructuring its business segments from three to five distinct units effective October 1, 2025. This reorganization aims to better align its operations with product and service offerings, focusing on Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences. The company is also in the process of combining its Biosciences and Diagnostic Solutions business with Waters Corporation, a transaction expected to close in early 2026, which will result in BD shareholders owning approximately 39.2% of the new entity.
Operationally, BD reported a total employee headcount of approximately 72,000 across 61 countries as of September 30, 2025. The company continues to invest in research and development, with R&D expenses amounting to $1.265 billion, representing 5.8% of total revenues. BD's international operations contributed significantly to its revenue, with U.S. sales reaching $12.790 billion and international sales at $9.049 billion, reflecting a 9.7% and 6.3% increase, respectively.
Looking ahead, BD anticipates continued growth driven by its strategic investments in innovation and geographic expansion, despite facing challenges such as inflation, supply chain disruptions, and regulatory scrutiny. The company remains focused on enhancing its product offerings and operational efficiencies to navigate the evolving healthcare landscape.
About BECTON DICKINSON & CO
Becton, Dickinson and Company (BD) is a global medical technology firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. Its three main segments—BD Medical, BD Life Sciences, and BD Interventional—serve healthcare institutions, physicians, researchers, and pharmaceutical companies worldwide. BD focuses on improving medication management, patient safety, infection prevention, diagnostics, and surgical care through innovative, quality-driven solutions distributed via direct and independent channels.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.